DNA damage signaling and apoptosis in preinvasive tubal lesions of ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 25, Issue 5, 2015, Pages 761-769

  Chene, Gautier ^a,b,c   Ouellet, Veronique ^a,b   Rahimi, Kurosh ^a,b   Barres, Veronique ^a,b   Caceres, Katia ^a,b   Meunier, Liliane ^a,b   Cyr, Louis ^a,b   De Ladurantaye, Manon ^a,b   Provencher, Diane ^a,b   Mes Masson, Anne Marie ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Institut du Cancer de Montreal   (Canada)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

Apoptosis; DNA damage response; Genomic instability; Ovarian cancer; STIC

Indexed keywords

ATM PROTEIN; BIM PROTEIN; CHECKPOINT KINASE 2; CYCLIN E; HISTONE H2AX; PROTEIN BAX; PROTEIN BCL 2; TELOMERIC REPEAT BINDING FACTOR 2; APOPTOSIS REGULATORY PROTEIN; DNA LIGASE; TUMOR MARKER;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE CHECKPOINT; FEMALE; GENOMIC INSTABILITY; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UTERINE TUBE; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; ENZYME IMMUNOASSAY; FALLOPIAN TUBE NEOPLASMS; FOLLOW UP; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; TISSUE MICROARRAY;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIOMARKERS, TUMOR; CYSTADENOCARCINOMA, SEROUS; DNA DAMAGE; DNA REPAIR ENZYMES; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 84930318019     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000196     Document Type: Article

References (42)

1. Chene G, Dauplat J, Radosevic-Robin N, et al. Tu-be or not tu-be: that is the questionI about serous ovarian carcinogenesis. Crit Rev Oncol Hematol. 2013;88:134-143.
2. Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26:995-1005.
3. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23:127-132.
4. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64.
5. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25: 3985-3990.
6. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52-56.
7. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236.
8. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009;3:165-170.
9. Kuhn E, Meeker A, Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol. 2010;34:829-836.
10. Chene G, Tchirkov A, Eymard-Pierre E, et al. Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions. Clin Cancer Res. 2013;19:2873-2882.
11. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864-870.
12. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier. Cell Cycle. 2007;6:2344-2347.
13. Gorgoulis VG, Vassiliou LVF, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907-913.
14. Smith J, Mun Tho L, Xu N, et al. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73-112.
15. Perona R, Moncho-Amor V, Machado-Pinilla R, et al. Role of CHK2 in cancer development. Clin Trans Oncol. 2008;10: 538-542.
16. Tanaka H, Mendonca MS, Bradshaw PS. DNA damage-induced phosphorylation of the human telomere-Associated protein TRF2. Proc Natl Acad Sci U S A. 2005;102:15539-15544.
17. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 1999;59:1693-1700.
18. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27:6398-6406.
19. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinomaVevidence supporting the clonal relationship of the two lesions. J Pathol. 2012;226:421-426.
20. Chene G, Tchirkov A, Penault-Llorca F. Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesionsVresponses. Clin Cancer Res. 2013;19:5255.
21. Raynaud CM, Hernandez J, Llorca FP, et al. DNA damage repair and telomere length in normal breast, preneoplastic lesions and invasive cancer. Am J Clin Oncol. 2010;33:341-345.
22. Lantuejoul S, Raynaud C, Salameire D, et al. Telomere maintenance and DNA damage response during lung carcinogenesis. Clin Cancer Res. 2010;16:2979-2988.
23. Raynaud CM, Jang SJ, Nuciforo P, et al. Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Ann Oncol. 2008;19:1875-1881.
24. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474: 609-615.
25. Shin JS, Hong A, Solomon MJ, et al. The role of telomeres and telomerase in the pathology of human cancer and aging. Pathology. 2006;38:103-113.
26. Frias C, Pampalona J, Genesca A, et al. Telomere dysfunction and genome instability. Front Biosci. 2012;17:2181-2196.
27. Stewart JA, Chaiken MF, Wang F, et al. Maintaining the end: roles of telomere proteins in end-protection, telomere replication and length regulation. Mutat Res. 2012;730:12-19.
28. Lantuejoul S, Soria JC, Morat L, et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res. 2005;11:2074-2082.
29. Oh BK, Kim YJ, Park C, et al. Up-regulation of telomere-binding proteins TRF1, TRF2 and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol. 2005;166:73-80.
30. Matsutani N, Yokozaki H, Tahara E. Expression of telomeric repeat binding factor 1 and 2 and TRF1Yinteracting nuclear protein 2 in human gactric carcinomas. Int J Oncol. 2001;19: 507-512.
31. Raynaud CM, Sabatier L, Philipot O, et al. Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. Crit Rev Oncol Hematol. 2008;66: 99-117.
32. Sehdev AS, Kurman RJ, Kuhn E, et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including RSF-1 (HBXAP), Cyclin E and fatty acid synthase. Mod Pathol. 2010;23: 844-855.
33. Chene G, Dauplat J, Cayre A, et al. The fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinomas [in French]. Bull Cancer. 2013;100:757-764.
34. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237-249.
35. Chene G, Lamblin G, Le Bail-Carval K, et al. Early preinvasive lesions in ovarian cancer. Biomed Res Int. 2014;ID 639252:1-11.
36. Auersperg N. The origin of ovarian cancersVhypotheses and controversies. Front Biosci (Schol Ed). 2013;5:709-719.
37. Chene G, Rahimi K, Mes Masson AM, et al. Surgical implications of the potential new tubal pathway for the ovarian carcinogenesis. J Minim Invasive Gynecol. 2013;20:153-159.
38. Kindelberger D, Lee Y, Hirsch MS, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169.
39. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin?. Am J Surg Pathol. 2010;34:1407-1416.
40. Nik NN, Shih IM, Kurman RJ. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol. 2014;9:27-45.
41. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160-4165.
42. Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinomas in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009;33:1878-1885.